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Abstract 
Inherited Primary Immunodeficiency (PID) disorders are associated with increased risk of 
malignancy that may relate to impaired antitumor immune responses or a direct role for PID 
germline mutations in tumorigenesis. We recently identified germline loss of function mutations in 
Janus Associated Kinase 1 (JAK1) causing primary immunodeficiency characterised by infections 
and associated with early onset, fatal high-grade bladder carcinoma. Somatic mutations in JAK1, 
required for immune cell signalling LQUHVSRQVHWRLQWHUIHURQJDPPD,)1ȖKDYHEHHQDVVRFLDWHG
with several non-hematopoietic and hematopoietic cancer cell types but pathogenic mechanisms 
remain largely unexplored.  Here we demonstrate that JAK1 is required for thH LQWULQVLF ,)1Ȗ
response of urothelial cells impacting immunogenicity and cell survival. Specifically, JAK1-
deficient urothelial cells showed reduced surface expression of major histocompatibility complex 
class II (MHC II), intercellular adhesion molecule-1 (ICAM-1) and programmed death-ligand-1 
(PD-/ DIWHU ,)1Ȗ VWLPXODWLRQ DQG ZHUH UHVLVWDQW WR ,)1Ȗ-induced apoptosis and lymphocyte-
mediated NLOOLQJ ,Q DGGLWLRQ ZH LGHQWLI\ D SUHYLRXVO\ XQNQRZQ UROH IRU ,)1Ȗ VLJQDlling in 
modulating urothelial differentiation. Together, our findings support a role for urothelial cell JAK1 
in immune surveillance and development of bladder cancer. Our results have implications for 
patients with rare JAK1 PID and, more broadly, inform development of biomarker and targeted 
therapies for urothelial carcinoma. 
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Introduction 
Widespread availability of next generation sequencing (NGS) has transformed the field of cancer, 
identifying candidate genes to enhance our understanding of tumorigenesis and enable stratification 
of patients for specific therapies. In the field of immunology, NGS has identified new monogenic 
forms of primary immunodeficiencies (PID): inherited disorders predisposing to infection, 
autoimmunity and malignancy. Genes identified to cause PID overlap with cancer susceptibility 
genes, so that clarifying the pathogenesis of PID has impact for oncology. We recently identified a 
new PID associated with compound homozygous loss of function mutations in the gene coding the 
signalling protein Janus-Associated Kinase 1 (JAK1) resulting in partial JAK1 deficiency (1). The 
clinical phenotype was characterised by immunodeficiency plus aggressive urothelial carcinoma 
that was fatal in the third decade of life, suggesting that impaired JAK1 function may be a 
predisposing factor for urothelial carcinoma. 
JAK1 belongs to a family of widely-expressed tyrosine kinases essential for signal transduction 
from multiple cytokine receptors through activators of transcription (STAT) proteins(2,3). 
Individual family members (JAK1, JAK2, JAK3 and Tyrosine kinase 2) associate with selected 
receptors and have non-redundant roles in cell signalling. Multiple receptors utilise JAK1 for signal 
transduction including members of the IL-2 receptor family (IL-2R, IL-7R, IL-9R and IL-15R), the 
IL-4 receptor family (IL-4R, IL-13R), the gp130 receptor family (IL-6R, IL-11R, LIF-R, OSM-R 
CT-1R, CNTF-R, NNT-1R/BSF- 3R and Leptin-R) and class II cytokine receptors (type I IFN-R, 
type II IFN-R, IL-10R (2).  Elucidating the non-redundant roles of JAK1 in cell biology has been 
complicated by the fact that complete JAK1-deficiency results in perinatal lethality as a result of 
neurological defects in murine models (3)precluding detailed examination of immune competence or 
malignancy risk. 
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Activation of the JAK1-GHSHQGHQW LQWHUIHURQJDPPD,)1ȖVLJQDlling pathway is known to have 
direct effects on tumour cells, impacting numerous cell programmes including growth, apoptosis, 
proliferation, differentiation and migration (4±8) ,Q DGGLWLRQ ,)1Ȗ LQGXFHV LPPXQRUHJXODWRU\
functions in cancer cells such as cytokine production, antigen presentation by major 
histocompatibility complexes (MHC) (9), expression of adhesion molecules such as intercellular 
adhesion molecule-1 (ICAM-1) (10)and ligands for receptors of immune checkpoints such as the 
programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) (11).  In mouse models, loss of 
,)1Ȗ VLJQDOOLQJ DFFHOHUDWHG WXPRXU LQLWLDWLRQ DQG SURJUHVVLRQ GHPRQVWUDWLQJ D GLUHFW LPSDFW RI
,)1Ȗ VLJQDOOLQJ RQ WXPRULJHQHVLV WKH WXPRXU PLFURHQYLURQPHQW DQG PHWastatic dissemination 
(5,12). 
To date, bladder urothelial carcinoma has not been described as a feature of other loss of function 
JAK-STAT RU ,)1Ȗ-related PID, although different types of tumours have been reported in these 
conditions, including disseminated cutaneous squamous cell carcinoma (13±16). Somatic mutations 
in JAK1 have been identified in multiple tumour types including high-risk bladder cancer, 
endometrial, colorectal, stomach, and prostate carcinomas (17±19) supporting the idea that 
alterations in JAK1 signalling, whether through loss or gain of function,  could play a role in the 
pathogenesis of some epithelial cancers. Somatic mutations predicted to cause loss of JAK1 
function are associated with reduced expression of IFN-associated genes in different tumour types 
(19). Although the cellular mechanisms have not been fully elucidated, truncating somatic JAK1 
mutations in gynaecological carcinomas reduced ,)1Ȗ-induced MHC class I expression at the 
tumour cell surface, which could reduce immune recognition and facilitate immune evasion (17).  
Here we examine the role of JAK1 in human urothelial cells and demonstrate a requirement of 
JAK1 for multiple functions including cell survival and interaction with immune cells. We also 
identify a potential role for JAK1 in modulating urothelial differentiation phenotype WKURXJK,)1Ȗ-
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signalling. Our findings provide new insight into immune and intrinsic signalling regulation of 
urothelial cells and support a role for JAK1 in the pathogenesis of bladder cancer. 
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Materials and methods 
The Cancer Genome Atlas Analysis 
Somatic variants for the muscle invasive bladder cancer (BLCA) cohort from The Cancer Genome 
Atlas (TCGA) were accessed from the Genome Data Commons(20) as part of dbGaP project 19625. 
Variants which overlapped the predominant JAK1 transcript (ENST00000342505.5) were extracted 
and their impact assessed using the Ensembl Variant Effect Predictor (21) including SIFT 4G (22) 
and Poly-Phen 2 (23), with additional analysis of deleterious effects using HMMvar v1.1.0(24). 
Mutations and their effects were presented against the JAK1 protein sequence (InterPro P23458). 
 
Ethical approval 
Blood samples and biopsies were obtained with ethical approval (National Research 
ethics numbers 08/H0720/46, 99/095 and 02/208) and informed consent from all subjects in 
accordance with the Declaration of Helsinki. 
 
Immortalised and normal human urothelial cell cultures 
An immortalized normal human urothelial (NHU) subline produced by retroviral transduction with 
human telomerase reverse transcriptase (hTERT) cells as detailed elsewhere (25), was used in this 
study.  The subline, referred to as Y235hTERT, was previously characterized at passage 40 against 
the pre-immortalised parental line (passage 7) using comparative genomic hybridization.  The 
Y235hTERT cell lines for this study were cultured using protocols detailed in full elsewhere (26) 
and used within 20 passages of the CGH analysis. JAK1 knock down (KD) and scrambled control 
(Sc) hTERT urothelial sub-lines were generated using lentiviral vectors expressing short hairpin 
RNA (shRNA) sequences and utilised for all experiments unless otherwise indicated.  shRNA 
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technology permitted generation of cell lines with sub-total deficiency similar to the effect of loss of 
function mutations seen in our patient (1).  
For differentiation studies only, normal human urothelial (NHU) cells obtained ethically with 
appropriate informed consent and Research Ethics Committee approvals were maintained in vitro as 
non-immortalized (finite) cells. For routine culture, NHU cells were grown as adherent monolayers 
RQ 3ULPDULD SODVWLFZDUH %' %LRVFLHQFHV LQ ORZ FDOFLXP  P0 NHUDWLQRF\WH VHUXP-free 
medium (KSFM) containing bovine pituitary extract and recombinant epidermal growth factor (Life 
Technologies) supplemented with 30 ng/ml cholera toxin (KSFMc).  NHU cells were sub-cultured 
by trypsinisation at just-confluence and used in experiments between passages 3-5.  Differentiation 
experiments described here were performed on five independent NHU cell cultures from five 
different donors.  Due to the finite nature of these lines, no genotyping of individual cell cultures 
was performed. Differentiation of NHU cells was induced in just-FRQIOXHQWFHOOFXOWXUHVXVLQJ(?ȝ0
troglitazone (TZ) as peroxisome proliferator-activated receptor-JDPPD 33$5Ȗactivating ligand 
ZLWKFRQFXUUHQW(?ȝ03'WREORFNHSLGHUPDOJURZWKIDFWor receptor (EGFR) activation, as 
previously described (27).  
All Y235hTERT cell lines and NHU cell cultures were tested regularly for contamination by 
Mycoplasma spp. using polymerase chain reaction-based kits and DNA-intercalating fluorescent 
stains for presence of extranuclear DNA.  For all stimulation experiments described, concentrations 
RI,)1ȖZHUHRSWLPLVHGIRUHDFKH[SHULPHQW 
 
Lentivirus preparation and transductions 
pGIPZ vectors carrying the short hairpin RNA against JAK1(TAGTACACACATTTCCATG)  or 
scrambled control (TGAACTCATTTTTCTGCTC) sequences as well as puromycin resistance 
cassette and turbo-GFP marker for selection were supplied by University College London Open 
Biosystems (London UK). Lentivirus stocks were prepared by transfection of 293T cells (80-90% 
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confluence) cultured in DMEM medium and 10% heat-inactivated fetal bovine serum, with the 
envelope plasmid 17.5 ȝg pMD.G2 (VSV-G/envelop), 32.5 ȝg p8.74 plasmid (gag-pol) and 25 ȝg 
vector construct with the transfection reagent PEI/Opti-0(0 IROORZLQJ WKH PDQXIDFWXUHU¶V 
instructions (Promega).  Medium was replaced 5h post transfection and medium was harvested after 
24 and 48 hours, cleared by centrifugation (4000 rpm, 5 min), filtered through 0.22µm filters and 
left to spin for 2h 4ºC 50,000g. Viruses were titrated on 293T cells by scoring GFP-positive cells 
(flow cytometry) 3 days post transduction. Virus stocks were stored at -80°C. Transductions of 
urothelial cells were carried out by infection at a multiplicity of infection of 1:10 for 6h, before 
replacing virus-containing mediumwith fresh medium. Cells were selected in puromycin-containing 
medium and the efficiency of transduction was assessed by percentage of GFP-positive cells. Loss 
of JAK1 expression in JAK1-deficient hTERT urothelial cells was verified by RT-PCR.  
 
Determination of mRNA levels by real time-quantitative polymerase chain reaction (RT-
qPCR) and reverse transcription polymerase chain reaction (RT-PCR) 
&HOOV ZHUH OHIW XQVWLPXODWHG RU VWLPXODWHG ZLWK  QJPO RI ,)1Ȗ IRU GLIIHUHQW WLPH SRLQWV 7RWDO
RNA from hTERT urothelial cells was extracted using RNAeasy kit (Qiagen). RNA from NHU 
cells was extracted in TRIzol® reagent (Thermo Fisher Scientific, Loughborough, UK); any 
contaminating DNA was digested using a DNA-free kit (Thermo Fisher Scientific). RNAs were 
converted to cDNA by reverse-transcription using QuantiTect reverse transcription kit (Qiagen).  
Determination of mRNA abundance was performed by RT-PCR using specific primers (Table S1) 
DQG 4XDQWL7HFW 6<%5 *UHHQ 3&5 .LW 4LDJHQ DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV )ROG
changes were calculated using the DDCT2 (-Delta Delta C(T)) method and results were normalised 
with respect to the values obtained for the endogenous GAPDH cDNA. 
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Flow Cytometry analysis 
Sc and KDhTERT urothelial cells, ± DGGLWLRQRIQJPORI ,)1Ȗ IRUGLIIHUHQW WLPHSRLQWVZHUH
detached using Accutase® solution (A6964, Sigma Aldrich), labelled with fluorescent-conjugated 
antibodies (see Table S2) and washed with phosphate buffered saline (PBS). For STAT1 
phosphorylation analysis, cells ±QJPO ,)1ȖIRU0 min were fixed and permeabilised using fix 
buffer I and Perm Buffer III (BD Biosciences) for 30 min at 4ºC, washed with PBS and labelled 
with 5µL anti-pSTAT1 antibody (BD Biosciences) for 60min in the dark. For all flow cytometry 
(BD LSRFortessa) experiments 10,000-30,000 gated events were collected and analysed using 
FlowJo software.  
 
Cell viability and Apoptosis assays 
Sc and .' K7(57 XURWKHOLDO FHOOV ZHUH VWLPXODWHG ZLWK ,)1Ȗ XVLQJ GLIIHUHQW WLPH SRLQWV DQG
concentrations. Alamar Blue® (AB), diluted 1:10 with KSFMc, was added to urothelial cells grown 
in 96-well plates (4,000 cells/well). After 3 hours incubation at 37°C, absorbance was measured at 
560 and 620 nm. AB reduction was calculated according to manufacturer's instructions (AbD 
Serotec, Kidlington, UK). Apoptosis was determined by flow cytometry using APC Annexin V 
apoptosis detection kit with Propidium Iodide (PI) accRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV
(BioLegend 640932).  
 
Lymphocyte Cytotoxicity Assay 
Healthy donor peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient and 
frozen in 10% dimethyl sulfoxide (DMSO). To control for differences in the frequency of 
lymphocyte subsets between donors, PBMCs collected from a single donor buffy coat were stored 
cryopreserved and used for all killing assays shown. PBMC were thawed and re-suspended in 
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RPMI (Invitrogen) with 10% heat-inactivated fetal bovine serum and monocytes removed by plastic 
adherence (1h, 37 °C). Urothelial cells were cultured in 96-well plates ± ,)1ȖQJPOIRUKDQG
subsequently co-cultured overnight with interleukin-2 (IL-2)25U/ml (Roche) + monocyte-depleted 
PBMCs (50:1). Cells were detached using Accutase® solution, washed with PBS and resuspended 
in 200 µl DNA staining solution which specifically stains nuclei in dead cells and allows 
identification of necrotic cells (NKTEST, Glycotope Biotechnology). Urothelial cells were gated 
based on green fluorescent protein (GFP) expression and analysed by flow cytometry.  
 
Immunohistochemistry 
5µM formalin-fixed tissue sections were dewaxed in xylene, then rehydrated through ethanol into 
water.  Antibodies are detailed in Table S3. Following appropriate antigen retrieval (Table S3),  
sections were incubated with optimally titrated primary antibodies and immunodetectedusing 
secondary antibodies linked to streptavidin-biotin horseradish peroxidase complex (DAKO), 
,P35(66([FHO3RO\PHUV\VWHP9HFWRUODEV, or BenchMark Ultra automated staining system 
(Ventana) (Table S3). $OOVOLGHVZHUHFRXQWHUVWDLQHGLQ0D\HU¶VKDHPDWR[\OLQDQGPRXQWHGLQ'3;
(Sigma).  Control slides and tissues were included to check specificity.  
 
Statistical analysis  
Statistical analysis was performed using Graphpad Prism 5.1 Software. Associations between 
JAK1-deficient and control cells were tested using one-way ANOVA and appropriate post-test, or a 
two-tailed Mann Whitney U test. A p value of<0.05 was considered significant.  
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Results 
Partial JAK1 deficiency impairs STAT1 phosphorylaWLRQ DQG H[SUHVVLRQ RI ,)1Ȗ-inducible 
genes in hTERT urothelial cells 
While our patient remains the only reported individual with partial JAK1 deficiency caused by 
germline loss of function mutations, somatic variants in JAK1have been described in other patients 
with very high-risk bladder cancer(18). Analysis of the muscle invasive bladder cancer (BLCA) 
cohort from The Cancer Genome Atlas (TCGA) (20) identified 31 different JAK1 variants in 25/412 
TCGA BLCA samples, including single nucleotide variants predicted to alter JAK1 protein function 
and nonsense/frameshift variants predicted to impair JAK1 signalling (Figure 1a).  
To model and test the impact of loss of JAK1 function in urothelial cells, we generated a JAK1 KD 
immortalised hTERT cell line using lentiviral vectors expressing shRNA sequences. Compared to 
control Sc shRNA, JAK1 shRNA substantially reduced JAK1 mRNA expression (Fig. S1a). To 
confirm functional knock down of JAK1, we studied JAK1-mediated activation of STAT1 proteins 
LQ UHVSRQVH WR ,)1Ȗ VWLPXODWLRQ XVLQJ IORZ F\WRPHWU\ :H REVHUYHG D VLJQLILFDQW GHFUHDVH LQ
67$7SKRVSKRU\ODWLRQIROORZLQJ,)1ȖVWLPXODWLRQLQWKH.'FHOOOLQHFRPSDUHGWRXQWUDQVGXFHG
and Sc shRNA lines, (p<0.05) (Fig. 1b,c and S1b). The effect was similar to the reduced, but not 
abolished, STAT1 phosphorylation observed in fibroblasts of the patient with JAK1 deficiency 
IROORZLQJ ,)1Ȗ VWLPXODWLRQ )LJ 6F Expression of mRNA for the interferon inducible 
transcription factor IRF1 was also significantly lower in KD than Sc cell lines following stimulation 
ZLWK,)1ȖLQGLFDWLQJLPSDLUHGGRZQVWUHDPJHQHUHJXODWLRQLQ-$.GHILFLHQF\)LJG5HGXFHG
UHVSRQVHVWR,)1ȖZHUHQRWGXHWRDOWHUDWLRQLQH[SUHVVLRQRIWKH,)1ȖUHFHSWRU,)1Ȗ5DV6FDQG
.'K7(57XURWKHOLDO FHOOV GLVSOD\HG FRPSDUDEOH ,)1Ȗ5VXUIDFH H[SUHVVLRQERWK DW EDVHOLQH DQG
IROORZLQJ,)1ȖVWLPXODWLRQ)LJHIDQG6E 
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JAK1 deficiency alters MHC, ICAM-1 and PD-L1 expression in hTERT urothelial cells  
It was previously shown that IFNs regulate expression of MHC, ICAM-1 and PD-L1 in cancer cells 
(9±11). We examined the expression of these cell surface molecules in JAK1-deficient and Sc 
hTERT urothelial cell lines EHIRUH DQG DIWHU ,)1Ȗ WUHDWPHQW (Fig. 2 and S2,3). While basal 
expression of MHCII was minimal LQERWK.'DQG6FFHOOV,)1ȖLQGXFHGH[SUHVVLRQRI0+&,,LQ
control cells that was significantly lower in the KD cells (p<0.05) (Fig. 2a,b, S2b, S3a).  As 
described for gynecological cancer cells bearing somatic JAK1 mutations (17), we also observed 
lower surface MHCI expression byJAK1-deficient hTERT urothelial cells compared with control 
cells at baseline. AIWHU,)1ȖVWLPXODWLRQ however, MHCI was upregulated by both control and KD 
cells with no significant difference (Fig. 2c,d, S2c, S3b).  Expression of ICAM-1 was reduced in 
KD cells at baseline and expressed at significantly lower levels DIWHU ,)1Ȗ VWLPXODWLRQ compared 
with Sc control (p<0,05. Fig. 2e,f, S2d, S3c). In keeping with the effects of other reported somatic 
PXWDWLRQV DVVRFLDWHG ZLWK ,)1Ȗ UHVLVWDQFH LQ FDQFHU FHOOV (28,29), we observed reduced PD-L1 
upregulation DIWHU ,)1Ȗ VWLPXODWLRQ LQ .' FHOOV FRPSDUHG WR 6F S Fig. 2g,h, S2e, S3d). 
Together these data indicate that JAK1 functions to regulate the expression of multiple 
immunomodulatory cell surface molecules in urothelial cells and that JAK1-deficiency alters 
urothelial immunomodulatory phenotype. 
 
JAK1 deficienc\LPSDLUVDSRSWRVLVLQUHVSRQVHWR,)1ȖLQK7(57XURWKHOLDOFHOOV 
JAK1 KD had no effect on basal growth kinetics of immortalised hTERT cell lines assessed using 
an Alamar Blue (AB) reduction assay. In both Sc and KD cell lines, the culture biomass increased 
VWHDGLO\ RYHU  GD\V LQGLFDWLQJ D VLPLODU LQFUHDVH LQ FHOO QXPEHU RYHU WLPH ,)1Ȗ VWLPXODWLRQ
significantly inhibited the rise in population in the Sc cell line (Fig.3a; p <0.05), in keeping with an 
anti-proliferative effect and/or increased cell death. By contrast, growth kinetics of the JAK1-
GHILFLHQWK7(57XURWKHOLDOFHOOSRSXODWLRQVKRZHGQRVLJQLILFDQWFKDQJHIROORZLQJ,)1Ȗtreatment 
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(Fig. 3a). To further investigate this, we tested whether JAK1-GHILFLHQWFHOOVDUHUHVLVWDQWWR,)1Ȗ-
induced apoptosis using Annexin V/PI staining.  In control Sc hTERT urothelial cells, ,)1ȖLQGXFHG
cell death (Fig. 3b,e) which was mainly due to an increase in cells in early apoptosis identified as an 
Annexin V+/PI dim population (Fig. 3c,e), with minimal effect on late apoptosis/necrosis 
(Fig.3d,e). In contrast, there was no significant impact of IFNȖ stimulation on any stage of cell 
death analysed in the KD cell line (Fig. 3 b-e), leading us to conclude that JAK1 is required for 
,)1Ȗ-mediated apoptosis in urothelial cells. Together, our data support a requirement for JAK1 in 
regulating urothelial cell survival and homeostasis LQUHVSRQVHWR,)1Ȗ 
 
Defective lymphocyte-mediated killing of JAK1-GHILFLHQW K7(57 XURWKHOLDO FHOOV DIWHU ,)1Ȗ
stimulation 
We next sought to establish whether the reduced MHCI and ICAM-1 levels observed would impair 
immune cell recognition of JAK1-deficient hTERT urothelial cells (9,10,30,31). We tested this 
using a lymphocyte assay where killing can be mediated by NK or CD8+ T cells through multiple 
mechanisms including shared perforin-granzyme and death receptor/death ligand mechanisms. ,)1Ȗ 
pre-treatment of the Sc hTERT cell line resulted in significant enhancement in urothelial cell lysis 
by third party, IL-2 expanded primary lymphocytes (measured as necrotic cells, p <0.05. Fig. 4 a,b).  
Importantly, lymphocyte mediated cell death was significantly reduced in KD compared to Sc cells 
IROORZLQJ,)1ȖSUH-treatment (p <0.05. Fig. 4c), suggesting that JAK1 deficiency confers resistance 
to immune cell killing.  
 
Role of JAK1 in urothelial cytodifferentiation  
Histological examination of the invasive urothelial carcinoma found in the JAK1-deficient patient 
revealed a heterogeneous tumour with distinct central and invasive regions (Fig. 5 and S4). The 
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tumour showed no infiltrating immune cells, with only infrequent cells identified in the stroma or 
vasculature (Fig. S5).  
Muscle-LQYDVLYH EODGGHU FDQFHUV DUH FODVVLILHG DV ³OXPLQDO´ XURWKHOLDO GLIIHUHQWLDWHG RU ³EDVDO-
OLNH´squamous differentiated) subtypes based on signature markers (32). Using antibodies against 
urothelial differentiation markers, the tumour was negative for uroplakin 3a, whilst cytokeratin 
(CK) 20 expression was weak and confined to the central region.  The squamous marker CK14 was 
present in a small patch of invasive cells but was otherwise absent. Transcriptional regulators of 
urothelial differentiation 33$5Ȗ, GATA3, FOXA1 and IRF1 showed nuclear localisation, with 
weak variable expression of IRF1; pSTAT1 expression was cytoplasmic and weak in both central 
and invasive regions. Human epidermal growth factor receptor 2 (HER2) expression was variable 
within the central portion of the tumour, with some areas containing scant membrane and 
cytoplasmic expression, but negative in other areas, including the invasive front. These findings 
indicated the tumour to be fundamentally luminal in subtype, albeit with a suppressed urothelial 
differentiation phenotype. GLYHQWKHGXDOUROHRI,5)LQERWK,)1ȖVLJQDOlLQJDQG33$5Ȗ-mediated 
urothelial differentiation, this led us to test experimentally whether JAK1 has a role in urothelial 
cell differentiation. 
As the immortalised hTERT urothelial cell line is not suitable for differentiation studies, non-
immortalised NHU cell cultures were generated from five individual donors. NHU cells were 
LQGXFHG WR GLIIHUHQWLDWH E\ FRDFWLYDWLRQ RI 33$5Ȗ DQG LQKLELWLRQ RI (*)5 VLJQDlling, using a 
combination of troglitazone and PD153035 (TZ/PD) (27). These conditions induce gene expression 
changes associated with urothelial GLIIHUHQWLDWLRQ YLD 33$5Ȗ-dependent transcription of 
intermediary transcription factors, including FOXA1 and IRF1 (33). As IRF1 knockdown limits 
uroplakin expressionand IRF1 induction was impaired in JAK1-deficient cells (Fig. 1b), we tested 
by RT-T3&5 ZKHWKHU ,)1Ȗ PRGXODWHV H[SUHVVLRQ RI JHQHV DVVRFLDWHG ZLWK ,)1Ȗ VLJQDOOLQJ DQG
urothelial cytodifferentiation pathways.  As expected, TZ/PD induced up-regulation of PPARG and 
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FOXA1 (Fig. 6DE ,)1Ȗ DORQH KDG D VPDOO HIIHFW UHVXOWLQJ LQ D ZHDN XS-regulation of IRF1, 
PPARG and the major histocompatibility class II transactivator (CIITA) (Fig. 6a,c,d). Surprisingly 
KRZHYHU VWLPXODWLRQ ZLWK ,)1Ȗ7=PD up-regulated all four genes and substantially increased 
expression of IRF1, FOXA1 and CIITA compared with TZ/PD alone (Fig. 6a-d). These data suggest 
WKDW WKH FRPELQDWLRQ RI ERWK ,)1Ȗ DQG 7=3' VLJQLILFDQWO\ LQFUHDVHV H[SUHVVLRQ RI WUDQVFULSWLRQ
factors involved in urothelial cytodifferentiation and supports a previously unknown role for JAK1 
in modulating urothelial phenotype.  
 
Discussion 
The fundamental importance of JAK1 signalling has been highlighted by perinatal lethality of JAK1 
knock-out mice (3) and, in keeping with this, germline mutations causing complete loss of JAK1 
function have not been described in humans. We recently reported the first case of germline loss of 
function mutations causing partial JAK1 deficiency in humans which resulted in immunodeficiency 
characterised by mycobacterial infection, suggesting a dominant effect on the IFNȖSDWKZD\ and 
high-grade bladder carcinoma (1). The early-onset and aggressive nature of the malignancy, along 
with the fact that JAK1 is a hotspot for damaging somatic mutations in bladder carcinoma (28), led 
us to investigate whether impaired JAK1 function may be a specific predisposing factor for 
urothelial carcinoma. The data presented here demonstrate that JAK1 is important for multiple 
aspects of urothelial cell biology and highlight mechanisms by which loss of JAK1 function may 
promote tumorigenesis in this cell type. 
Using a JAK1-deficient urothelial cell line model, we show that loss of JAK1 function impaired 
LQGXFWLRQ RI DSRSWRVLV LQ UHVSRQVH WR ,)1Ȗ VXJJHVWLQJ D UROH IRU -$. LQ UHJXODWLQJ LQWrinsic 
urothelial cell homeostasis. In addition, JAK1-deficient urothelial cell lines demonstrated reduced 
surface expression levels of ICAM-1 following ,)1Ȗ VWLPXODWLRQ ZKLFK ZDV DVVRFLDWHG ZLWK
resistance to lymphocyte-mediated cell lysis that is known to correlate with cell surface expression 
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of this molecule (10,34). While we did not observe a significant effect of JAK1 deficiency on ,)1Ȗ-
mediated upregulation of MHCI in our model, JAK1 was shown to be required for expression of 
MHC II that can mediate tumour and self-antigen presentation in non-professional antigen 
presenting cells (35). This difference could be explained by the fact that MHC I is highly expressed 
constitutively on urothelial cells whereas MHC II expression, like ICAM-1, is induced de novo by 
,)1ȖDFWLYLW\)LJDQGKHQFHGHPRQVWUDWHVDKLJKO\VSHFLILFGLUHFWHGUHVSRQVH 
Together these data suggest that JAK1-deficient urothelial cells are less susceptible to ,)1Ȗ-
mediated apoptosis, immune cell recognition and immune-mediated cell death. The absence of an 
LPPXQH LQILOWUDWH REVHUYHG LQ WKH SDWLHQW¶V WXPRXU E\ LPPXQRKLVWRFKHPLVWU\ VXSSRUWV our 
conclusion that loss of JAK1 in bladder cancer cells results in a poorly immunogenic tumour. ,)1Ȗ
is of specific relevance in bladder cancer as it is a major cytokine released by tumour infiltrating 
lymphocytes thought to be important for anti-tumour responses and has potential for use as a 
biomarker of outcome in this condition (36±39). It has already been reported that damaging 
PXWDWLRQV LQ WKH ,)1Ȗ VLJQDOOLQJ SDWKZD\ DQG DQWLJHQ SUHVHQWDWLRQ SDWKZD\ are associated with 
metastasis and higher resistance to the checkpoint blocking therapy with anti-PD-L1/PD-1 in a 
number of tumour types, including bladder cancer (29,30,40). Our data suggest loss of function 
JAK1 mutations are a risk factor for lower tumour cell PD-L1 expression which could impair 
responsiveness to anti-PD-1 therapy used for advanced urothelial carcinoma (41). Further 
correlation of tumour genetics with clinical response to treatment is required to test this in practice. 
In addition to impacting immune-UHODWHGIXQFWLRQVZHREVHUYHGDSRWHQWLDOUROHIRU-$.DQG,)1Ȗ
signalling in urothelial cell differentiation. It has been shown that NHU cells can be induced to 
GLIIHUHQWLDWHXVLQJ33$5ȖOLJDQGVDQGFRQFXUUHQW(*)5LQKLELtion, for example using TZ/PD (27). 
In this study, we show that ,)1ȖKDGDVLJQLILFDQWHIIHFWRQWKHLQGXFWLRQRIWKHWUDQVFULSWLRQIDFWRUV
IRF1 and FOXA1, both known to be involved in urothelLDOFHOOGLIIHUHQWLDWLRQLQGXFHGE\33$5Ȗ
activation (33). In particular, IRF1 is a common downstream mediator for 33$5Ȗ DQG ,)1Ȗ
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signalling pathways influencing both urothelial differentiated phenotype and immune cell 
interactions. This suggests that IRF1 may be a potential novel target for modulating immunotherapy 
outcomes in urothelial cancer. Further research isneHGHG WR XQGHUVWDQG WKH PHFKDQLVPV RI ,)1Ȗ
LQWHUDFWLRQZLWK33$5ȖDQG(*)5VLJQDlling in urothelial cell differentiation and tumorigenesis.  
In summary our findings highlight previously unknown roles for JAK1 in urothelial cell immune 
recognition and differentiation. Our data suggest that loss of JAK1 function through germline or 
somatic mutation promotes malignant transformation of urothelial cells, which are intrinsically less 
immunogenic.  
Our results add further weight to arguments for sequencing urothelial cell tumours for clinical trials 
RI LPPXQRWKHUDS\ DJHQWV WR WHVW ZKHWKHU WKH PXWDWLRQDO EXUGHQ RI -$. DQG RWKHU ,)1Ȗ-related 
genes represent a biomarker for responsiveness to treatment in bladder cancer, which can more 
accurately predict the clinical outcome of these patients. 
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Figure legends 
Figure 1. STAT1 phosphorylation and expression of IRF1mRNA is impaired in JAK1-
deficient hTERT urothelial cells. (A) JAK1 protein (InterPro P23458) structure showing core 
domains, TCGA BLCA variants and their predicted impact. Protein domains: FERM (4.1 protein, 
ezrin, radizin, moesin domain), PHD (pleckstrin homology-like domain), SH2 (Src homology 2), S-
TY-PK (unknown specificity serine-threonine/tyrosine protein kinase), SY-PK (serine-tyrosine 
protein kinase). Variants: nonsense (red cross), missense (yellow inverted triangle), synonymous 
(green triangle), frameshift (purple square). Variant effects: S (SIFT score < 0.05), P (Poly-Phen 
score > 0.908), p (Poly-3KHQVFRUH!	++00YDUVFRUH!$VLQJOH¶875
modifier mutation not shown. (B,C) Analysis of JAK/STAT signalling by flow cytometry in 
untransduced (Unt), Sc and KD hTERT immortalised urothelial cell lines after stimulation with 
,)1Ȗ QJPO IRU K 'DWD $ LV IURP D UHSUHVHQWDWLYH H[SHULPHQW GDWD % LV IURP WKUHH
independent experiments. Two-tailed Mann Whitney test. (D) RTqPCR analysis of IRF1 mRNA 
expression from KD and Sc hTERT immortalised urothelial cell lines DIWHUVWLPXODWLRQZLWK ,)1Ȗ
(1ng/ml). Data is from four independent experiments. Two-tailed Mann Whitney test.*P <0.05 
Error bars represent the SE.(E,F) Flow cytometry analysis of IFNGR expression in KD and Sc 
hTERT immortalised urothelial cell lines IROORZLQJVWLPXODWLRQZLWK,)1ȖQJ/ml) for two days. 
The graph shows mean values ± SD. Data is from three independent experiments. One-way 
ANOVA with Tukey's Multiple Comparison Test.   
 
Figure 2. Analysis of MHC I/II, ICAM-1 and PD-L1 expression in hTERT urothelial cells by 
Flow Cytometry. Flow cytometry analysis of surface receptor expression in KD and Sc hTERT 
immortalised urothelial cell lines before DQG DIWHU ,)1Ȗ VWLPXODWLRQ 0HDQ IOXRUescence intensity 
and percentage of positive cells are shown for (A,B) MHCII (C, D) MHC I (E-F) ICAM-1 and (G-
H) PD-L1 expression. Data is from four independent experiments for (A-F) and from three 
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independent experiments (G-H). One-way ANOVA with Tukey's Multiple Comparison post-test. 
Graphs shows mean values ± SE and regulation of the expression compared to untreated.*P <0.05. 
Error bars represent the SE. 
 
Figure 3. JAK1-deficient hTERT urothelial cells demonstrate preserved population growth 
and reduced apoSWRVLVLQUHVSRQVHWR,)1Ȗ  (A) KD and Sc hTERT immortalised urothelial cell 
lines were cultured with addition of $ODPDU%OXH$%G\HDQGVWLPXODWHGZLWK,)1ȖQJPOIRU
the given time points. The capacity of viable cells to reduce AB dye was used as a proxy for cell 
number. Data A is from five independent experiments. (B,C,D,E) KD and Sc hTERT urothelial cell 
lines were stimulated with the given FRQFHQWUDWLRQVRI,)1ȖIRUGD\V Percentage of early and late 
apoptosis was quantified with Annexin V/PI apoptosis detection kit by flow cytometry. Data B,C 
and D are from five independent experiments, data E is from a representative experiment. One-way 
ANOVA with Tukey's Multiple Comparison post-test. Error bars represent the SE. 
 
Figure 4. JAK1-deficient hTERT urothelial cells showed reduced lymphocyte-mediated 
killing LQUHVSRQVHWR,)1ȖJAK1-deficient and Sc hTERT immortalised urothelial cell lines were 
SUHWUHDWHG RU QRW ZLWK ,)1Ȗ DQG FXOWXUHG RYHUQLJKW ZLWK 8PO ,/-2 and monocyte-depleted 
PBMCs (50:1). (A,B) Necrosis induction in JAK1-deficient and Sc hTERT immortalised urothelial 
cell lines. One-way ANOVA with Dunn's multiple comparisons post-test. (C) Relative change of 
necrosis compared to untreated. Two-tailed Mann Whitney U test. Data is from five independent 
experiments. *P < 0.05. Error bars represent the SE. 
 
)LJXUH  ,PPXQRKLVWRFKHPLFDO ODEHOOLQJ RI SDWLHQW¶V WXPRXU XVLQJ SDQHO RI DQWLERGLHV
DJDLQVWGLIIHUHQWLDWLRQ83.D&.&.WUDQVFULSWLRQIDFWRU33$5Ȗ*$7$)2;$
28 
 
IRF1), and cell signalling (pSTAT1 and HER2) markers.  Images from central region of the 
tumour, except where marked as invasive.   Parallel human tissue controls for antibodies are shown 
in supplementary Figure S3.   Scale bar = 12 µm. 
 
Figure 6. ([SUHVVLRQRI,)1Ȗ-regulatory genes and intermediary transcription factors in NHU 
cells by RT-qPCR. RT-qPCR analysis of gene expression in fivenon-immortalized NHU cell 
cultures REWDLQHGIURPILYHGLIIHUHQWGRQRUVZLWKRUZLWKRXW,)1Ȗ8PODQGRU7=0
PD153035 (1 µM) stimulation for 48h compared with the vehicle-only (0.1% DMSO) control. Data 
are from five independent experiments each using a different NHU cell donor.  One-way ANOVA 
with Tukey's Multiple Comparisons Test. *P<0.05. Error bars represent the SE. 
 
 
 
